On Wednesday, Shares of Pfizer Inc. (NYSE:PFE), gained 1.95% to $31.97.
The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. recently declared the launch of the Palbociclib Collaborative Adjuvant Study, or PALLAS. This global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group (BIG), German Breast Group (GBG), National Surgical Adjuvant Breast and Bowel Project (NSABP) and PrECOG, LLC (PrECOG). The PALLAS trial will evaluate whether the addition of IBRANCE® (palbociclib), developed by Pfizer, to standard therapy will improve disease-free survival and prevent the disease from recurring. Patients treated in this study will have cancers that are hormone receptor-positive (HR+), meaning their growth is fueled by the hormone estrogen, but are negative for human epidermal growth factor receptor 2 (HER2-), a different tumor-associated protein. About 60 to 65 percent of breast cancers in the United States fall into this category.
“We are delighted that Alliance was chosen to co-lead the PALLAS trial together with our partners at ABCSG,” said Monica M. Bertagnolli, MD, president and chief executive officer of AFT, and group chair and principal investigator of the Alliance for Clinical Trials in Oncology. “This exciting study examines a new CDK 4/6 inhibitor that has already demonstrated an impact for breast cancer patients with metastatic disease. The aim is to determine whether IBRANCE can also improve the disease-free survival rate in patients with surgically resectable disease.”
“After intensively working together among trial leadership on the scientific conception, operational preparation and seamless transatlantic cooperation for this clinical trial, we are excited that this study, with the potential to revolutionize adjuvant therapy for the most common type of breast cancer, is now ready to start,” said Professor Michael Gnant, MD, FACS, president of the ABCSG, and head of the Breast Health Center Vienna. “We are convinced that this global venture has potential to bring great benefit to our breast cancer patients.”
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of QUALCOMM Incorporated (NASDAQ:QCOM), inclined 1.53% to $55.86, during its last trading session.
QUALCOMM Incorporated declared that its partner, Qualcomm Technologies, Inc. (QTI), is extending its mobile security technology leadership with the introduction of Qualcomm® Snapdragon™ Smart Protect. The forthcoming Qualcomm® Snapdragon™ 820 processor is the first platform offering Snapdragon Smart Protect, providing real-time, on-device machine learning designed to support accurate and effective detection of zero-day malware threats for improved personal privacy and device security. Snapdragon Smart Protect is also the first application to utilize Qualcomm® Zeroth™ technology, augmenting conventional anti-malware solutions by supporting on device real-time malware detection, classification, and cause analysis using an advanced cognitive computing behavioral engine.
Snapdragon Smart Protect complements existing signature-based anti-malware solutions by analyzing and identifying new threats preceding to new signature updates. OEMs and mobile anti-malware application providers can also use Snapdragon Smart Protect API’s to perform valuable causal analysis, offering users and the mobile industry real-time information of identified threats.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI).
Finally, Best Buy Co., Inc. (NYSE:BBY), ended its last trade with 2.79% gain, and closed at $36.43.
The Board of Directors of Best Buy has authorized the payment of a regular quarterly cash dividend of $0.23 per common share. The quarterly dividend is payable on October 6, 2015, to shareholders of record as of the close of business on September 15, 2015. The company had 344,258,055 shares of common stock issued and outstanding as of August 1, 2015.
Best Buy Co., Inc. operates as a retailer of technology products, services, and solutions in the United States and internationally. Its stores offer consumer electronics comprising primarily of television and home theaters; digital cameras and camcorders; DVD and Blu-ray players; portable electronics, such as MP3 devices, headphones and speakers, car stereo, navigation and satellite radio; and related accessories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
